CEO Leheny A. Rachel Continues Buying Shares, Signaling Strong Confidence in CalciMedica’s Breakthrough Pipeline
Insider buying signals confidence in CalciMedica’s inflammatory‑disease pipeline, with CEO Leheny A. Rachel accumulating 186,729 shares at $0.80.
4 minutes to read